NASDAQ:APRE Aprea Therapeutics Q3 2026 Earnings Results & Report $0.42 -0.02 (-5.41%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$0.43 +0.01 (+3.08%) As of 11/13/2026 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aprea Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.09 versus the -$0.0725 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeBefore Market OpensConference Call8:30 AM ET Aprea Therapeutics EPS ResultsActual EPS-$0.09Consensus EPS -$0.0725Beat/MissMissed by -$0.0175One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAprea Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$308 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aprea Therapeutics Q3 2026 Earnings FAQ Did Aprea Therapeutics beat earnings estimates for Q3 2026? Aprea Therapeutics (NASDAQ:APRE) reported earnings of -$0.09 per share for Q3 2026, missing the consensus estimate of -$0.0725. The report was announced on Wednesday, November 4, 2026. Aprea Therapeutics Earnings HeadlinesAprea Therapeutics, Inc. (NASDAQ:APRE) Stock Has Average Price Target of $2.80November 13 at 2:29 AM | americanbankingnews.comAprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceNovember 5, 2026 | globenewswire.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 14 at 1:00 AM | Porter & Company (Ad)Aprea Q3 Loss Widens On R&D Costs; Updated APR-1051 Phase 1 Data Due November 20November 5, 2026 | rttnews.comAprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMAprea Therapeutics Announces Third Quarter 2026 Financial ResultsNovember 4, 2026 | globenewswire.comSee More Aprea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email. Email Address About Aprea TherapeuticsAprea Therapeutics (NASDAQ:APRE) (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its research is centered on small-molecule treatments intended to address molecular abnormalities that contribute to tumor growth and resistance to treatment. The company’s lead historical program was eprenetapopt, also known as APR-246, an investigational therapy designed to reactivate mutant p53, a tumor-suppressor protein frequently altered in cancer. Eprenetapopt was studied in hematologic malignancies, including TP53-mutant myelodysplastic syndromes and acute myeloid leukemia. Aprea has also worked on next-generation oncology programs and novel compounds intended to expand treatment options for patients with genetically defined cancers. As a clinical-stage company, its product candidates remain subject to clinical testing and regulatory review, and the company does not currently market an approved commercial product.View Aprea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
